The FDA approved a regimen of one maintenance dose every 8 weeks for lebrikizumab-lbkz in adults and children aged 12 years and older who weigh at least 88 pounds with moderate to severe atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results